# Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments

> **NCT07517315** · — · TEMPORARILY_NOT_AVAILABLE · sponsor: **Sun Pharma Advanced Research Company Limited**

## Conditions studied

- CML, Relapsed
- CML, Refractory

## Interventions

- **DRUG:** K0706

## Key facts

- **NCT ID:** NCT07517315
- **Lead sponsor:** Sun Pharma Advanced Research Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** TEMPORARILY_NOT_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07517315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07517315, "Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07517315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*